<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR22">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hodi</surname>
    <given-names>FS</given-names>
   </name>
   <name>
    <surname>Chiarion-Sileni</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Gonzalez</surname>
    <given-names>R</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial</article-title>
  <source>Lancet Oncol</source>
  <year>2018</year>
  <volume>19</volume>
  <issue>11</issue>
  <fpage>1480</fpage>
  <lpage>1492</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30700-9</pub-id>
  <?supplied-pmid 30361170?>
  <pub-id pub-id-type="pmid">30361170</pub-id>
 </element-citation>
</ref>
